Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)
Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
A Phase I of Olaparib with Radiation Therapy in Patients With Inflammatory, Loco-regionally
Advanced or Metastatic TNBC (triple negative breast cancer) or Patient With Operated TNBC
with Residual Disease.